Inclusion Criteria:

          -  Participant with histologically confirmed adenocarcinoma of the prostate.

          -  Participant with metastatic disease documented by positive bone scan and/or measurable
             soft tissue metastatic lesions by computed tomography (CT) or magnetic resonance
             imagining (MRI).

          -  Participant who has serum testosterone level is ≤1.73 nanomoles per liter (nmol/L) (50
             nanograms per deciliter).

          -  Participant who has progressive disease at study entry demonstrated during continuous
             androgen-deprivation therapy (ADT)/post orchiectomy.

          -  Participant with adequate organ function.

          -  Participant with Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

        Exclusion Criteria:

          -  Participant who was treated with cytochrome P450 (CYP)17 inhibitors (including
             abiraterone acetate, TAK-700, TOK-001, and ketoconazole).

          -  Participant who was treated with abemaciclib or any cyclin dependent kinase 4 and 6
             (CDK4 and 6) inhibitors.

          -  Participant who has prior cytotoxic chemotherapy for metastatic castration-resistant
             prostate cancer (mCRPC), prior radiopharmaceuticals for prostate cancer (PCa), or
             prior sipuleucel-T.

          -  Participant who has gastrointestinal disorder affecting absorption or inability to
             swallow large pills.

          -  Participant who has clinically active or chronic liver disease, moderate/severe
             hepatic impairment, ascites, or bleeding disorders secondary to hepatic dysfunction.

          -  Participant who has known or suspected central nervous system metastatic disease.

          -  Participant who was treated with drugs known to be strong inhibitors, or strong or
             moderate inducers of cytochrome P450 3A4 (CYP3A4) and the treatment cannot be
             discontinued or switched prior to starting study treatment.